Aptamer Group (LSE:APTA), the York-based developer of Optimer binders, has announced a set of board and senior Leadership changes, adding fresh therapeutic expertise as the small-cap biotech pushes deeper into drug delivery. In an announcement on 16 November 2026, the FTSE AIM All Share index constituent said Dr Paloma Giangrande would join as a non-executive director, Dr James McNamara would become Head of Oligonucleotide Therapeutic Development, and Dr David Bunka would step down from the board to focus on research and development.
What the company does
Aptamer Group (LSE:APTA) develops Optimer binders, synthetic molecules built from nucleic acids that can bind specific targets in a similar way to antibodies. The company offers discovery and development services to pharmaceutical, diagnostics and research customers, and increasingly seeks licensing deals where its Optimers are built into partners' products. It is also developing Optimer-based delivery vehicles designed to carry therapeutics to particular tissues.
Latest developments
The new non-executive director brings experience of drug programmes; the company said earlier programmes associated with Dr Giangrande were acquired by Bristol Myers Squibb for US$1.5 billion. Dr McNamara's appointment underlines the group's growing interest in oligonucleotide therapeutics. On 12 November 2026 the company also announced a voluntary price condition on directors' options.
On 26 October 2026 Aptamer unveiled a cost-sharing collaboration with Pharmahungary Group, a developer of microRNA therapeutics, to generate preclinical data on Optimer delivery vehicles targeting heart and skeletal muscle. Under the terms, each party funds its own work and keeps its own intellectual property. Pharmahungary will fund preclinical studies that the company said would typically cost £300,000 to £500,000, while Aptamer will own 50% of the combined Optimer-miRNA therapeutic. Aptamer said the deal requires no unbudgeted spending and does not change its cash runway. Earlier in 2026 the group announced an Ebola diagnostic test programme and a rapid testing programme for fortified foods.
Financial picture
Full-year results for the 12 months to 30 June 2026, published on 13 October, showed Revenue up 28% to £1.5 million. The company reported an adjusted EBITDA loss of £2.3 million and administrative expenses of £3.2 million. Cash stood at £4.4 million, following a £4.1 million Equity raise; the company announced a placing and a retail offer in March 2026. Management said this position funds operations into calendar 2028. The sales pipeline had risen to £7.0 million by September 2026, and the company said it was moving key pharmaceutical relationships onto multi-year master service agreements and had signed new licensing agreements for enzyme-modulating Optimers. The company does not pay a dividend.
Sector and index context
Aptamer is one of many early-stage life sciences companies on AIM, a market that has traditionally provided growth Capital to UK biotech. Such companies have faced a demanding funding environment in recent years, with investors favouring businesses that can demonstrate commercial traction and disciplined cash management. Aptamer's emphasis on revenue growth, partnerships and runway reflects that backdrop within the wider FTSE AIM All Share Index.
Key risks
The company remains loss-making and dependent on converting its pipeline into contracted revenue. Licensing income and milestone payments are uncertain in both size and timing. Therapeutic delivery programmes are at a preclinical stage and may not succeed. Further equity funding could be needed in future, which may dilute existing shareholders, and the shares can be volatile given the company's small size.
What to watch next
Investors will watch for conversion of the £7.0 million pipeline into contracts, progress with the Pharmahungary collaboration, and further licensing deals. Updates on the oligonucleotide strategy under the new leadership, and on cash burn against the stated runway into 2028, will also be in focus.






Please wait processing your request...